Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Specialty Medicine Compounding Pharmacy, P.C.
WARNING LETTER
•Specialty Medicine Compounding Pharmacy, P.C.•November 5, 2013

Specialty Medicine Compounding Pharmacy, P.C. – FDA Warning Letter, Nov 5, 2013

Record Details

On August 31, 2015, the FDA issued a Warning Letter to Specialty Medicine Compounding Pharmacy, P.C., following an inspection from October 21 to November 5, 2013. The inspection revealed the firm was producing drug products without valid prescriptions for individually-identified patients and exhibited serious deficiencies in sterile drug production.

Violations included: - **Lack of Valid Prescriptions:** A portion of drug products were produced without valid prescriptions for individually-identified patients, making them ineligible for statutory exemptions under FDCA section 503A and misbranded under section 502(f)(1). - **Adulterated Products:** - Sterile drug products were prepared, packed, or held under insanitary conditions (e.g., exposed skin on operators' faces during gowning, failure to demonstrate adequate protection of ISO 5 area by hoods), leading to adulteration under section 501(a)(2)(A). - FDA testing of dextrose 50% injectable revealed mold in unopened vials, indicating adulteration under sections 501(a)(1) and 501(b) due to failure to meet USP standards for sterility, quality, and purity. - **Significant CGMP Violations (for drugs produced without individual prescriptions), causing adulteration under section 501(a)(2)(B):** 1. Failure to establish and follow

Company
Specialty Medicine Compounding Pharmacy, P.C.
Inspection date
November 5, 2013
Product type
Drugs
Office
Detroit District Office
Person
  • Art O. Czabaniuk (Program Division Director)
View Company Profile

ID · 545666fd-bac9-417f-8449-d410a5bc44be

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 353a21 U.S.C. 352(f)(1)21 U.S.C. 351(a)(1)21 U.S.C. 351(b)21 U.S.C. 351(a)(2)(A)21 U.S.C. 331(k)21 CFR 21021 CFR 21121 CFR 211.113(b)

Full citation text and observation details available on the Dashboard.

Other documents for Specialty Medicine Compounding Pharmacy, P.C.
  • 483 - 2013-11-05November 5, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Specialty Medicine Compounding Pharmacy, P.C.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.